Acrivon Therapeutics is a next-generation precision medicine company focused on neurological cancer and inflammatory fibrosis.
Their approach, Acrivon Predictive Precision Proteomics (AP3), enables an exact match between disease-driving pathways and drug mechanisms.
The company's leadership team is comprised of experts with diverse backgrounds in medicine, research, and business operations.
Precision Medicine Focus
Acrivon Therapeutics specializes in precise alignment of dysregulated pathways and drug actions.
Development Sites
The company operates development and clinical biomarkers sites in Boston, and precision-proteomics sites in Lund/Copenhagen.
Accomplished Leadership
The leadership team includes individuals with extensive experience in oncology, drug development, and corporate operations.
- Acrivon Therapeutics aims to revolutionize precision medicine by linking specific pathways to drug efficacy.
- The company's technology, AP3, has shown promising results in target identification and drug profiling.
With a focus on precision and innovation, Acrivon Therapeutics is poised to make significant advancements in the field of precision medicine.